Active Ingredient(s): Elvitegravir
FDA Approved: * September 24, 2014
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vitekta Overview

Elvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed[1] by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008.[2][3][4] The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild.[5] ...

Read more Vitekta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Vitekta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 150mg, 85mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vitekta: (2 results)

Sorted by National Drug Code
  • 61958-1301 Vitekta 85 mg Oral Tablet, Film Coated by Gilead Sciences, Inc.
  • 61958-1302 Vitekta 150 mg Oral Tablet, Film Coated by Gilead Sciences, Inc.

Other drugs which contain Elvitegravir or a similar ingredient: (4 results)